Venetoclax-Based Regimen in Refractory or Relapsed Pediatric Acute Lymphoblastic Leukemia

Children with R/R ALL who received the VEN-based regimen achieved a high remission rate with an acceptable safety profile. Significantly, the VEN-based regimen was effective in patients with R/R ETP with MRD-negative results while also proving beneficial for KMT2A-rearranged, highlighting VEN-chemotherapy as a treatment option for remission.